MRNA250103P49000
- 8.20
- 0.000.00%
Moderna Newsroom
Moderna (MRNA) Rises But Trails Market: What Investors Should Know
Unusual Options Activity: PG, DAL and Others Attract Market Bets, PG V/OI Ratio Reaches 133.3
EST Jan 3rd Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
Moderna Options Spot-On: On January 3rd, 117.68K Contracts Were Traded, With 657.56K Open Interest
On January 3rd ET, $Moderna(MRNA.US)$ had active options trading, with a total trading volume of 117.68K options for the day, of which put options accounted for 31.48% of the total transactions, and
The S&P 500's 10 Worst Performing Stocks in 2023 Fell Again in 2024
Moderna Options Spot-On: On January 2nd, 112.55K Contracts Were Traded, With 646.17K Open Interest
On January 2nd ET, $Moderna(MRNA.US)$ had active options trading, with a total trading volume of 112.55K options for the day, of which put options accounted for 77.7% of the total transactions, and
These Battered S&P 500 Stocks Could Be Ripe for a Turnaround in 2025
Why Moderna Inc. (MRNA) Is Skyrocketing
The U.S. stock market officially closed for 2024! Among the components of the three major stock indices, who performed the best and who performed the worst?
AppLovin, a constituent stock of the Nasdaq, surged by 713%, becoming the biggest dark horse, with an increase more than four times that of AI leader NVIDIA.
Equity Markets Fall Intraday as 2024 Draws to Close
Peering Into Moderna's Recent Short Interest
These Stocks Are Moving the Most Today: Super Micro, Moderna, Nvidia, MicroStrategy, Palantir, VeriSign, Sangamo, and More -- Barrons.com
These Are the Best and Worst Stocks This Year
This Biotech Is One of the S&P 500's Worst Performers. It Looks Too Cheap. -- Barrons.com
Morgan Stanley: Personalized cancer vaccines and ADCs will become the main catalysts in the oncology treatment Industry by 2025.
Morgan Stanley stated in a recent research report that personalized cancer vaccines and antibody-drug conjugates (ADCs) will become one of the major innovations in cancer biotechnology next year.
Here Are Morgan Stanley's Key Oncology Catalysts for 2025
Moderna Options Spot-On: On December 27th, 138.19K Contracts Were Traded, With 648.69K Open Interest
On December 27th ET, $Moderna(MRNA.US)$ had active options trading, with a total trading volume of 138.19K options for the day, of which put options accounted for 33.9% of the total transactions,
Unusual Options Activity: ANET, MSTR and Others Attract Market Bets, ANET V/OI Ratio Reaches 138.7
EST Dec 27th Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Moderna Options Spot-On: On December 26th, 149.21K Contracts Were Traded, With 640.82K Open Interest
On December 26th ET, $Moderna(MRNA.US)$ had active options trading, with a total trading volume of 149.21K options for the day, of which put options accounted for 85.5% of the total transactions,
Unusual Options Activity: MSTR, HIMS and Others Attract Market Bets, MSTR V/OI Ratio Reaches 35.0
EST Dec 26th Morning Delivery - In the last two hours of trading, 7 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
2024's Top and Bottom Nasdaq-100 Performers Includes NVDA, APP, INTC, MRNA, and More